MicroTech Medical (Hangzhou) Co (HKSE:02235) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02235 MicroTech Medical (Hangzhou) Co Ltd HKSE:02235
80 GF Score
Price HK$7.26
GF Value HK$15.94
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is MicroTech Medical (Hangzhou) Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:02235
80GF Score
MicroTech Medical (Hangzhou) Co Ltd HKSE:02235
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MicroTech Medical (Hangzhou) Co (HKSE:02235) Overvalued in 2026?

Based on GuruFocus' analysis, MicroTech Medical (Hangzhou) Co stock appears to be undervalued. The current stock price of HK$7.26 is trading 54.5% below its estimated GF Value™ of HK$15.94. GuruFocus considers MicroTech Medical (Hangzhou) Co to be Possible Value Trap.

Key valuation signals for HKSE:02235:

  • FFO:
  • GF Value™: HK$15.94 vs. price of HK$7.26 (54.5% below fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MicroTech Medical (Hangzhou) Co Business Description

Address No. 108 Liuze Street, Cangqian Street, Yuhang District, Zhejiang Province, Hangzhou, CHN
MicroTech Medical (Hangzhou) Co Ltd is focused on diabetes management, providing both diabetes treatment and diabetes monitoring medical devices to improve the diabetes management in China and globally. The Group operates in a large and fast-growing diabetes monitoring, treatment and management market in China and globally with unmet clinical needs. The company derives a majority of its revenue from China.
80GF Score

Get the complete analysis for HKSE:02235

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.26
Price
HK$15.94
GF Value